Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study - BMC Endocrine Disorders
Source : https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-01139-8
Background IDegLira is a fixed-ratio combination of insulin degludec and liraglutide with proven efficacy against simpler regimens and non-inferiority against basal-bolus insulin therapy. However, the evaluation of its real-world effectiveness...
Conclusions: Treatment with IDegLira over 18 months resulted in greater HbA1c reductions, weight loss versus gain, and a lower rate of hypoglycaemia versus ICT in people with type 2 diabetes.
Influence of sodium-glucose Co-transporter 2 inhibitors on clinical and biochemical markers of dehydration during the Holy Ramadan
Source : https://www.sciencedirect.com/science/article/abs/pii/S187140212200220X?via=ihub
Excess glucose excretion and diuresis with sodium-glucose co-transporter 2 inhibitors may cause dehydration during Ramadan. * Clinical and biochemical markers of dehydration existed with sodium-glucose co-transporter 2 inhibitors during Ramadan....
Conclusions: Significant clinical and biochemical markers of dehydration were noticed among users of SGLT2i during the Holy Ramadan.
-
Dr Hamid3yrImportant study to detect the potential alteration of hydration status in adult Muslims with type 2 diabetes mellitus (T2D) who used SGLT2i during Ramadan.
Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36027585/
Only a few meta-analyses evaluated the effect of finerenone on cardiovascular events in type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). The main aim of this meta-analysis was...
Conclusion: Overall, finerenone treatment showed a great benefit of reducing the risk of MACEs, all-cause mortality, myocardial infarction, and new-onset hypertension events in patients with T2DM and CKD.
Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308087/
Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D)...
Conclusion/Relevance: In this real-world study, patients with T2D and CKD treated with subcutaneous semaglutide for 12 months significantly improved glycemic control and decreased weight. Albuminuria decreased by >50% in patients with macroalbuminuria. The administration of GLP-1RA in patients with T2D and CKD was safe and well tolerated.
-
Dr Hamid3yrPatients with T2D and CKD who develop macroalbuminuria have a greater risk of cardiovascular disease mortality than progression to ESKD
Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors
Source : https://www.eurekaselect.com/article/125504
Type 2 diabetes mellitus (T2DM) is a set of metabolic disorders specified by hyperglycemia as a result of abnormalities in insulin secretion or sensitivity. Chronic kidney disease (CKD) and cardiovascular...
Relevance: Combinations such as empagliflozin and linagliptin, ertugliflozin and metolazone, dapagliflozin and sacubitril-valsartan and many more show promising results. Here, we have reviewed the ongoing and completed clinical trials, addressed current theories, and discussed necessary future research to explain the possible risks and...
-
Dr Hamid3yrChronic kidney disease (CKD) and cardiovascular disease (CVD) are the widespread co-morbidities of T2DM and share risk factors for onset and progression